Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells – Implications for systemic control

•Treatment with EBRT + BT induces distinct modulation of peripheral CD4/CD8 ratio in high-grade prostate cancer patients.•Patients with long term response that received EBRT + BT showed distinct changes in CD4+ and CD8 + T cells compared to EBRT alone.•PBMCs demonstrate potential to be predictive bi...

Full description

Saved in:

Bibliographic Details
Published in:	Radiotherapy and oncology Vol. 191; p. 110077
Main Authors:	Wang, H., Mendez, L., Morton, G., Loblaw, A., Chung, H.T., Cheung, P., Mesci, A., Escueta, V., Petchiny, T.N., Huang, X., White, S.D., Downes, M., Vesprini, D., Liu, S.K.
Format:	Journal Article
Language:	English
Published:	Ireland Elsevier B.V 01-02-2024
Subjects:	Brachytherapy Immune cells Prostate cancer Radiotherapy Brachytherapy Immune cells Radiotherapy Prostate cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•Treatment with EBRT + BT induces distinct modulation of peripheral CD4/CD8 ratio in high-grade prostate cancer patients.•Patients with long term response that received EBRT + BT showed distinct changes in CD4+ and CD8 + T cells compared to EBRT alone.•PBMCs demonstrate potential to be predictive biomarkers. This exploratory study is a follow up to our previous investigation of immune response in the circulation of high-grade Gleason 9 prostate cancer patients treated with EBRT + BT compared to EBRT alone. Notably, EBRT + BT demonstrates the potential to elicit an effect on CD4/CD8 ratio which may have attributed to improved clinical response to therapy. Our findings show promise for leveraging circulating immune cells as predictive biomarkers for radiotherapy response.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0167-8140 1879-0887 1879-0887
DOI:	10.1016/j.radonc.2023.110077